News NurExone Biologic Inc. Deutsche Boerse AG

Equities

J90

CA67059R1091

Market Closed - Deutsche Boerse AG Other stock markets 07:48:47 05/07/2024 pm IST			5-day change	1st Jan Change
0.44 ^EUR	-0.45%		0.00%	+157.31%

28/06	NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves	CI
29/05	NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Updates from NurExone: Growth Conference Presentation and Website Relaunch	05/07	AQ
NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves	29/06	CI
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market	29/06	AQ
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development	22/06	AQ
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application	11/06	AQ
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders	05/06	AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	29/05	AQ
NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05	CI
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	18/05	AQ
NurExone Biologic Announces OTCQB Listing And DTC Eligibility	25/04	MT
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	25/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	22/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	20/04	AQ
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	02/04	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	28/03	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	23/03	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	16/03	AQ
NurExone Biologic Building a Research and Development Facility in Israel	09/03	MT
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	09/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NurExone Biologic Inc. Deutsche Boerse AG

Equities

J90

CA67059R1091

Summary

Filters